YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News Blast

Oct 17, 2005

Scientists from J. Craig Venter Institute, Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high-throughput sequencing. The mutations provide the potential for highly targeted cancer therapies.

GlaxoSmithKline (GSK) and Illumina have signed a commercial, multiyear, genotyping services agreement. Illumina will use Sentrix arrays in conjunction with GoldenGate and Infinium arrays to conduct genetic studies for thousands of samples provided by GSK. Illumina also announced deals with the National Cancer Institute for the purchase and installation of a BeadLab and the Wellcome Trust Sanger Institute  for the design of a custom, multi-sample Sentrix BeadChip.

Solexa researchers, with the Delaware Biotechnology Institute and the University of Delaware, reported in Science “the most comprehensive analysis to date of the small RNA component of the transcriptome.” The assay can be used to elucidate small RNAs in any plant or animal species, notably humans.

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.